摘要
目的:调查2014–2018年我国七城市二肽基肽酶-4抑制剂(DPP-4i)的使用情况,为临床合理用药提供参考数据。方法:随机抽取七个城市87家医院的处方信息,对销售金额、用药频度等进行统计分析。结果:共纳入202554张处方,累计销售3368.50万元。七个城市年复合增长率为55.46%。西格列汀的销售金额及用药频度均为第一位,分别为1676.20万元和210.18万日。沙格列汀和维格列汀分列第二、三位。DPP-4i类药物的限定日费用5年内呈持续下降趋势,结合序号比值分析后发现西格列汀的经济性较好(序号比值1.0),而阿格列汀的经济性较差(序号比值0.83)。结论:2014–2018年我国七城市DPP-4i销售金额累计前两位的是西格列汀和沙格列汀,西格列汀的药物经济性在同类药品中较好。
Objective:To evaluate the utilization of dipeptidyl peptidase-4 inhibitor(DPP-4 i)in seven cities in China from 2014 to 2018 in order to provide references for rational drug use.Methods:Prescriptions of DPP-4 i were randomly selected from 87 hospitals in seven cities.Prescription information including consumption sum,medication frequency and so on was statistically analyzed.Results:A total of 202554 prescriptions were included.The consumption sum was 33.685 million yuan.The compound annual growth rate of seven cities in five years was 55.46%.The consumption sum and medication frequency of sitagliptin were 16.762 million yuan and 2.1018 million days respectively,which were both ranked the first in all DDP-4 i.Saxagliptin and vildagliptin were ranked the second and the third respectively.The defined daily cost of DPP-4 i showed a continuous downward trend within 5 years.Results of the serial number ratio analysis showed that the economy of sitagliptin was better(serial number ratio 1.0)while that of alogliptin was the worst(serial number ratio 0.83).Conclusion:DDP-4 i with the top 2 total consumption sum in seven cities of China from 2014 to 2018 were sitagliptin and saxagliptin.Sitagliptin had better economical efficiency than other DDP-4 i.
作者
周洋
石秀锦
彭文星
魏娟娟
林阳
ZHOU Yang;SHI Xiu-jin;PENG Wen-xing;WEI Juan-juan;LIN Yang(Department of Pharmacy,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
出处
《中国药物应用与监测》
CAS
2019年第6期369-372,382,共5页
Chinese Journal of Drug Application and Monitoring
基金
北京市医院管理局临床药学发展专项经费资助项目(ZYLX201805)
关键词
二肽基肽酶-4抑制剂
降糖药
使用现状
Dipeptidyl peptidase-4 inhibitor
Hypoglycemic agent
Utilization analysis
